Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs2285489
rs2285489
0.010 GeneticVariation BEFREE We retrospectively examined whether <i>ADAMTS13</i> rs2285489 affected the transplant outcomes in a cohort of 281 patients who underwent unrelated human leukocyte antigen (HLA)-matched bone marrow transplantation for hematologic malignancies. 30626079

2019

dbSNP: rs397507444
rs397507444
0.010 GeneticVariation BEFREE Differential effects of the methylenetetrahydrofolate reductase polymorphisms (C677T and A1298C) on hematological malignancies among Latinos: a meta-analysis. 31188929

2019

dbSNP: rs121913507
rs121913507
KIT
0.010 GeneticVariation BEFREE The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation. 29643855

2018

dbSNP: rs121913682
rs121913682
KIT
0.010 GeneticVariation BEFREE The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation. 29643855

2018

dbSNP: rs1057520009
rs1057520009
0.010 GeneticVariation BEFREE Recent reports have shown molecular alterations in the gene encoding XPO1 and showed a mutation hotspot (E571K) in the following two hematological malignancies with similar phenotypes and natural histories: primary mediastinal diffuse large B cell lymphoma and classical Hodgkin's lymphoma. 28196522

2017

dbSNP: rs11536889
rs11536889
0.010 GeneticVariation BEFREE We retrospectively examined whether or not genetic variations in toll-like receptor 1 (rs5743551, -7202GQ>A), toll-like receptor 2 (rs7656411, 22215G>T), and toll-like receptor 4 (rs11536889, +3725G>C) affected transplant outcomes in a cohort of 365 patients who underwent unrelated HLA-matched bone marrow transplantation (for hematologic malignancies through the Japan Marrow Donor Program. 28484092

2017

dbSNP: rs1800023
rs1800023
0.010 GeneticVariation BEFREE We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A>G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. 28487238

2017

dbSNP: rs1801157
rs1801157
0.010 GeneticVariation BEFREE Several recent studies have shown that <i>SDF1</i>-3'A polymorphism (rs1801157) is associated with susceptibility to hematological malignancy, but published studies' results are disputed. 28352190

2017

dbSNP: rs5743551
rs5743551
0.010 GeneticVariation BEFREE We retrospectively examined whether or not genetic variations in toll-like receptor 1 (rs5743551, -7202GQ>A), toll-like receptor 2 (rs7656411, 22215G>T), and toll-like receptor 4 (rs11536889, +3725G>C) affected transplant outcomes in a cohort of 365 patients who underwent unrelated HLA-matched bone marrow transplantation (for hematologic malignancies through the Japan Marrow Donor Program. 28484092

2017

dbSNP: rs7656411
rs7656411
0.010 GeneticVariation BEFREE We retrospectively examined whether or not genetic variations in toll-like receptor 1 (rs5743551, -7202GQ>A), toll-like receptor 2 (rs7656411, 22215G>T), and toll-like receptor 4 (rs11536889, +3725G>C) affected transplant outcomes in a cohort of 365 patients who underwent unrelated HLA-matched bone marrow transplantation (for hematologic malignancies through the Japan Marrow Donor Program. 28484092

2017

dbSNP: rs1057519766
rs1057519766
0.010 GeneticVariation BEFREE Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD. 26891877

2016

dbSNP: rs767464424
rs767464424
0.010 GeneticVariation BEFREE Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD. 26891877

2016

dbSNP: rs777017502
rs777017502
0.010 GeneticVariation BEFREE Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD. 26891877

2016

dbSNP: rs25487
rs25487
0.010 GeneticVariation BEFREE The current meta-analysis indicated that the Arg399Gln polymorphism in the XRCC1 gene might be a risk factor for hematological malignancies in Asians or for leukemia. 25619474

2015

dbSNP: rs13347
rs13347
0.010 GeneticVariation BEFREE In conclusion, our results indicate that among investigated single nucleotide polymorphisms (SNPs), only CD44 rs13347 has an impact on the efficacy of HSCs mobilization in patients with hematologic malignancies. 24680978

2014

dbSNP: rs1799782
rs1799782
0.010 GeneticVariation BEFREE The current meta-analysis indicated that the Arg194Trp polymorphism in the XRCC1 gene might be not a risk factor for hematological malignancies. 24414482

2014

dbSNP: rs25489
rs25489
0.010 GeneticVariation BEFREE The current meta-analysis indicated that the Arg280His polymorphism in the XRCC1 gene might not be a risk factor for hematological malignancies. 24096581

2014

dbSNP: rs909253
rs909253
0.010 GeneticVariation BEFREE In the subgroup analysis, significant association of rs909253 was found in adenocarcinoma (OR = 1.16, P (z) < 0.001) and hematological malignancy (OR = 1.10, P (z) < 0.001). 24136744

2014

dbSNP: rs2229094
rs2229094
0.010 GeneticVariation BEFREE Subgroup meta-analysis suggested that rs2239704 was likely to increase the risk of hematological malignancy (OR = 1.10, 99% CI = 1.01-1.20, P = 0.023, I(2) = 0.0%), and rs2229094 was specific for the increased risk of adenocarcinoma (OR = 1.33, 99% CI = 1.11-1.59, P = 0.002, I(2) = 0.0%). 24349304

2013

dbSNP: rs2239704
rs2239704
0.010 GeneticVariation BEFREE Subgroup meta-analysis suggested that rs2239704 was likely to increase the risk of hematological malignancy (OR = 1.10, 99% CI = 1.01-1.20, P = 0.023, I(2) = 0.0%), and rs2229094 was specific for the increased risk of adenocarcinoma (OR = 1.33, 99% CI = 1.11-1.59, P = 0.002, I(2) = 0.0%). 24349304

2013

dbSNP: rs3921
rs3921
0.010 GeneticVariation BEFREE This study retrospectively examined the impact of a single nucleotide variation (rs3921, +1642C>G) in the CXCL10 gene on transplant outcomes in a cohort of 652 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies. 23291247

2013

dbSNP: rs8192284
rs8192284
0.010 GeneticVariation BEFREE The IL-6 receptor rs8192284 was associated with an increased risk of hematologic malignancy (combined ORG 1.42, 95%CI 1.03-1.96), including multiple myeloma (ORG 1.39, 95%CI 0.99-1.95). 24059848

2013

dbSNP: rs757874631
rs757874631
CBL
0.010 GeneticVariation BEFREE We analyzed 77 samples from hematologic malignancies, identifying a somatic mutation in CBL (p.C381R) in one patient with T-ALL that was associated with a uniparental disomy at the CBL locus and a germline heterozygous mutation in one patient with JMML. 22591685

2012

dbSNP: rs148704956
rs148704956
0.010 GeneticVariation BEFREE This study retrospectively examined the impact of a single-nucleotide polymorphism (rs2275913, G197A) in the IL-17 gene of a total 510 recipients with hematologic malignancies and their unrelated donors on the clinical outcomes in HLA-matched myeloablative (discovery study) and nonmyeloablative (validation study) BMT through the Japan Marrow Donor Program (JMDP). 21217785

2011

dbSNP: rs78245253
rs78245253
0.010 GeneticVariation BEFREE Hence, we concluded GATA-2 L359 V is exclusively associated with CML progression but not other hematological malignancies and P250A is a new single nucleotide polymorphism. 19304323

2009